[go: up one dir, main page]

HUP9800882A2 - Enterális fluoxetin pelletek és eljárás előállításukra - Google Patents

Enterális fluoxetin pelletek és eljárás előállításukra

Info

Publication number
HUP9800882A2
HUP9800882A2 HU9800882A HUP9800882A HUP9800882A2 HU P9800882 A2 HUP9800882 A2 HU P9800882A2 HU 9800882 A HU9800882 A HU 9800882A HU P9800882 A HUP9800882 A HU P9800882A HU P9800882 A2 HUP9800882 A2 HU P9800882A2
Authority
HU
Hungary
Prior art keywords
fluoxetine
enteral
subject
preparation
active ingredient
Prior art date
Application number
HU9800882A
Other languages
English (en)
Inventor
Neil Robert Anderson
Roger Garrick Harrison
Daniel Frederick Lynch
Peter Lloyd Oren
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25349313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9800882(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HU9800882D0 publication Critical patent/HU9800882D0/hu
Publication of HUP9800882A2 publication Critical patent/HUP9800882A2/hu
Publication of HUP9800882A3 publication Critical patent/HUP9800882A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

A találmány a hatóanyagként az ismert antidepresszáns gyógyszerhatóanyagőt, a flűőxetint tartalmazó enterális készítményrevőnatkőzik. A jelen találmány tárgyát képező enterális flűőxetinpellet a) flűőxetinből és egy vagy több, gyógyszerészetilegelfőgadható kötőanyagból álló magőt; b) adőtt esetben elválasztóréteget; c) hidrőxiprőpil-metilcellűlóz-acetát-szűkcinátból (HPMCAS)és gyógyszerészetileg elfőgadható kötőanyagból álló enterális réteget;d) adőtt esetben végső főrmát adó réteget tartalmaz. A találmánytárgyát képezi tővábbá az enterális flűőxetin pellet előállításáraszőlgáló eljárás is. ŕ
HU9800882A 1997-05-29 1998-04-15 Fluoxetine enteric pellets and process for their preparation HUP9800882A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/867,196 US5910319A (en) 1997-05-29 1997-05-29 Fluoxetine enteric pellets and methods for their preparation and use

Publications (3)

Publication Number Publication Date
HU9800882D0 HU9800882D0 (en) 1998-05-28
HUP9800882A2 true HUP9800882A2 (hu) 2000-03-28
HUP9800882A3 HUP9800882A3 (en) 2000-07-28

Family

ID=25349313

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9800882A HUP9800882A3 (en) 1997-05-29 1998-04-15 Fluoxetine enteric pellets and process for their preparation

Country Status (45)

Country Link
US (3) US5910319A (hu)
JP (1) JP3210288B2 (hu)
KR (1) KR100549473B1 (hu)
CN (2) CN1161109C (hu)
AR (1) AR011728A1 (hu)
AT (1) AT408068B (hu)
AU (1) AU726690B2 (hu)
BE (1) BE1011925A3 (hu)
BR (1) BR9801989A (hu)
CA (1) CA2234826C (hu)
CH (1) CH693018A5 (hu)
CO (1) CO4940407A1 (hu)
CZ (1) CZ290582B6 (hu)
DE (1) DE19823940B4 (hu)
DK (1) DK176776B1 (hu)
ES (1) ES2161574B1 (hu)
FI (1) FI119971B (hu)
FR (1) FR2763846B1 (hu)
GB (1) GB2325623B (hu)
GR (1) GR980100188A (hu)
HU (1) HUP9800882A3 (hu)
ID (1) ID20343A (hu)
IL (1) IL124073A (hu)
IT (1) ITMI980908A1 (hu)
LT (1) LT4477B (hu)
LU (1) LU90245B1 (hu)
LV (1) LV12176B (hu)
MY (1) MY118139A (hu)
NL (1) NL1009259C2 (hu)
NO (1) NO317743B1 (hu)
NZ (1) NZ330192A (hu)
PE (1) PE75399A1 (hu)
PL (1) PL192293B1 (hu)
PT (1) PT102152B (hu)
RO (1) RO120043B1 (hu)
RS (1) RS49827B (hu)
RU (1) RU2164405C2 (hu)
SE (1) SE522914C2 (hu)
SG (1) SG72805A1 (hu)
SI (1) SI9800128B (hu)
SV (1) SV1998000052A (hu)
TR (1) TR199800937A3 (hu)
TW (1) TWI239838B (hu)
UA (1) UA48193C2 (hu)
ZA (1) ZA983173B (hu)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
CA2374039C (en) * 1999-05-20 2011-01-11 Elan Corporation Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
ES2162560B1 (es) * 1999-06-25 2002-07-16 Rodriguez Concepcion Pena Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
UA75580C2 (uk) 1999-09-03 2006-05-15 Апбі Холдінгс, Ллк Застосування дапоксетину або його фармацевтично прийнятної солі в лікарському засобі для лікування розладу статевої функції та промисловий виріб для його застосування
CN1094347C (zh) * 1999-11-15 2002-11-20 广东药学院药物研究所 一种治疗前列腺良性增生症的控释微丸及其制备方法
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
ES2185452B2 (es) * 2000-08-01 2004-03-16 Cinfa S A Lab Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
JP4181738B2 (ja) * 2000-08-25 2008-11-19 信越化学工業株式会社 腸溶性コーティング製剤の製造方法
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
WO2002038126A2 (en) * 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
CA2457385A1 (en) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2002361495A1 (en) * 2002-12-24 2004-07-22 Lupin Limited Enteric coated fluoxetine composition
US8614247B2 (en) * 2003-04-10 2013-12-24 Institut National De La Sante Et De La Recherche Medicale Methods for preventing, attenuating or treating pulmonary hypertension using a serotonin transporter inhibitor, and pharmaceutical compositions for the treatment thereof
MXPA05012900A (es) 2003-05-30 2006-02-22 Ranbaxy Lab Ltd Derivados de pirrol sustituidos.
US20050176693A1 (en) * 2003-08-12 2005-08-11 Boissonneault Roger M. Method of intermittent administration of a pharmaceutical for the treatment of conditions associated with a female's menstrual cycle
EP1699458A4 (en) * 2003-12-30 2012-04-25 Reddys Lab Ltd Dr PHARMACEUTICAL COMPOSITION
JP4277904B2 (ja) * 2004-04-30 2009-06-10 アステラス製薬株式会社 経口投与用時限放出型粒子状医薬組成物及び該組成物を含有する口腔内速崩壊錠
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
TWI306858B (en) * 2004-12-23 2009-03-01 Teva Pharma Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
JP5153629B2 (ja) * 2005-08-02 2013-02-27 ルピン・リミテッド 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物
CA2627599A1 (en) 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
WO2007062119A1 (en) * 2005-11-23 2007-05-31 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
BRPI0708191A2 (pt) * 2006-02-24 2012-05-29 Teva Pharma " composições farmacêuticas de fluvastatina sódica "
CN101057837B (zh) * 2006-04-20 2010-12-22 湖南九典制药有限公司 一种右旋酮洛芬肠溶微丸及制备方法
EP2016066A4 (en) * 2006-05-10 2010-11-24 Reddys Lab Ltd Dr PROCESS FOR PREPARING DULOXETINE
RU2008148547A (ru) * 2006-05-22 2010-06-27 Тева Фармасьютикл Индастриес Лтд. (Il) Фармацевтические композиции, включающие дулоксетина гидрохлорид с замедленным высвобождением
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
BRPI0714915A2 (pt) * 2006-07-28 2013-05-28 Reddys Lab Ltd Dr composiÇço farmacÊuticas; formas de dosagem farmacÊutica; e processo para o preparo de uma composiÇço farmacÊutica
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
US20080103105A1 (en) * 2006-09-22 2008-05-01 Braincells, Inc. HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
US20090226517A1 (en) * 2008-02-06 2009-09-10 Vinita Umashankar Vyas Pharmaceutical formulations comprising duloxetine
NZ590852A (en) 2008-07-16 2013-03-28 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands trans-1{ 4-[2-[4-(2,3-dichlorophenyl)-piperizin-1-yl]-ethyl]-cyclohexyl} -3,3-dimethyl-urea also known as cariprazine
US20110172249A1 (en) * 2008-09-03 2011-07-14 Takeda Pharmaceutical Company Limted Method for improving absorbability of preparation, and preparation having improved absorbability
CN101804145B (zh) * 2009-02-12 2012-11-14 杭州赛利药物研究所有限公司 一种大蒜油肠溶微丸胶囊及其制备方法
EP2477614A2 (en) * 2009-09-17 2012-07-25 Cadila Healthcare Limited Pharmaceutical compositions for reducing alcohol-induced dose dumping
EP2540318B1 (en) * 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
RU2442572C1 (ru) * 2010-12-23 2012-02-20 Ольга Львовна Титова Энтеросолюбильная оболочка и композиция для ее получения
EP2844297B1 (en) 2012-05-02 2018-08-15 Capsugel Belgium NV Aqueous dispersions of controlled release polymers and shells and capsules thereof
CN102716084B (zh) * 2012-06-29 2013-09-25 海南美大制药有限公司 盐酸氟西汀脂质体固体制剂
CA2883077C (en) 2012-09-03 2017-03-07 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN106456555B (zh) * 2014-05-20 2019-05-07 陶氏环球技术有限责任公司 包含酯化纤维素醚的胶囊壳
US10179110B2 (en) 2014-05-20 2019-01-15 Dow Global Technologies Llc Dispersion comprising a partially neutralized esterified cellulose ether
WO2015187874A1 (en) * 2014-06-07 2015-12-10 Structure-Ase, Inc. A method for the detection and/or diagnosis of eating disorders and malnutrition using x-ray diffraction
US10471152B2 (en) 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
AU2018250628A1 (en) * 2017-04-13 2019-12-05 Chase Therapeutics Corporation Pharmaceutical combination and its use for treating synucleinopathies
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
CN107898942B (zh) * 2017-11-24 2021-01-26 一力制药(罗定)有限公司 一种感冒清热胶囊及其制备方法
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
WO2022115054A1 (en) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Enteric coated duloxetine compositions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
JPS517116A (en) 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CH649216A5 (de) 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
US4444778A (en) * 1981-08-27 1984-04-24 Coughlin Shaun R Method and composition for treating atherosclerosis
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4847092A (en) * 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4918242A (en) 1988-03-30 1990-04-17 Aldrich Chemical Company, Inc. Novel optically 1,3-phenoxypropylhalides
CA1337955C (en) * 1988-09-26 1996-01-23 Thomas A. Almquist Recoating of stereolithographic layers
US4999382A (en) * 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
JPH04202124A (ja) * 1990-11-29 1992-07-22 Fuji Kagaku Kogyo Kk 噴霧乾燥造粒法による薬物放出の制御された製剤の製造法
AU1429092A (en) * 1991-02-04 1992-09-07 Timothy J Barberich Methods of use and compositions of r(-) fluoxetine
WO1992019241A1 (en) * 1991-05-07 1992-11-12 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
AU668386B2 (en) * 1992-03-25 1996-05-02 Depomed Systems, Incorporated Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
JPH06293633A (ja) * 1993-04-05 1994-10-21 Shin Etsu Chem Co Ltd 水性腸溶性エマルジョンの製造方法
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
ATE198547T1 (de) * 1993-11-03 2001-01-15 Isomed Inc Mizelleförmige feinteilige pharmazeutische zusammensetzungen
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
JPH08109126A (ja) * 1994-10-07 1996-04-30 Amano Pharmaceut Co Ltd 耐衝撃性腸溶性顆粒剤およびこれを含有する錠剤
JPH08245423A (ja) * 1995-03-06 1996-09-24 Shionogi & Co Ltd 水系腸溶性コーティング液
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
BR9801989A (pt) 2000-02-08
NL1009259C2 (nl) 1998-12-01
NO982197D0 (no) 1998-05-14
FR2763846A1 (fr) 1998-12-04
IE980284A1 (en) 2000-07-12
SI9800128A (sl) 1999-02-28
TR199800937A2 (xx) 1999-10-21
US5910319A (en) 1999-06-08
RO120043B1 (ro) 2005-08-30
FI119971B (fi) 2009-05-29
DK176776B1 (da) 2009-08-10
SI9800128B (sl) 2000-04-30
CA2234826A1 (en) 1998-11-29
PE75399A1 (es) 1999-08-17
JPH10330253A (ja) 1998-12-15
HU9800882D0 (en) 1998-05-28
GB2325623B (en) 1999-04-14
CN1161109C (zh) 2004-08-11
MY118139A (en) 2004-09-30
LU90245B1 (fr) 2002-07-31
SE9801336D0 (sv) 1998-04-17
AR011728A1 (es) 2000-08-30
SG72805A1 (en) 2000-05-23
US5985322A (en) 1999-11-16
CH693018A5 (de) 2003-01-31
ITMI980908A1 (it) 1999-10-28
CO4940407A1 (es) 2000-07-24
USRE39030E1 (en) 2006-03-21
SE522914C2 (sv) 2004-03-16
FR2763846B1 (fr) 2001-05-18
TR199800937A3 (tr) 1999-10-21
LT4477B (lt) 1999-03-25
RS49827B (sr) 2008-08-07
RU2164405C2 (ru) 2001-03-27
HUP9800882A3 (en) 2000-07-28
ES2161574B1 (es) 2002-06-16
PT102152B (pt) 2000-09-29
LV12176B (lv) 1999-03-20
DE19823940B4 (de) 2010-04-29
BE1011925A3 (fr) 2000-03-07
FI980846L (fi) 1998-11-30
UA48193C2 (uk) 2002-08-15
LT98058A (en) 1998-10-26
CZ114398A3 (cs) 1998-12-16
GB9807939D0 (en) 1998-06-10
PL192293B1 (pl) 2006-09-29
TWI239838B (en) 2005-09-21
ES2161574A1 (es) 2001-12-01
ATA93198A (de) 2001-01-15
NO982197L (no) 1998-11-30
PT102152A (pt) 1998-12-31
GB2325623A (en) 1998-12-02
CN1285189A (zh) 2001-02-28
SE9801336L (sv) 1998-11-30
LV12176A (lv) 1998-12-20
ZA983173B (en) 1999-10-15
NO317743B1 (no) 2004-12-13
GR980100188A (el) 1999-01-29
AT408068B (de) 2001-08-27
AU726690B2 (en) 2000-11-16
SV1998000052A (es) 1999-03-16
KR19980086622A (ko) 1998-12-05
JP3210288B2 (ja) 2001-09-17
FI980846A0 (fi) 1998-04-16
CZ290582B6 (cs) 2002-08-14
ID20343A (id) 1998-12-03
NZ330192A (en) 1999-08-30
CA2234826C (en) 2000-12-19
PL326134A1 (en) 1998-12-07
LU90245A1 (hu) 1998-11-30
CN1200924A (zh) 1998-12-09
IL124073A (en) 2002-02-10
YU16598A (en) 1999-11-22
KR100549473B1 (ko) 2006-03-23
CN1212834C (zh) 2005-08-03
HK1034902A1 (en) 2001-11-09
AU6904898A (en) 1998-12-03
DE19823940A1 (de) 1998-12-03

Similar Documents

Publication Publication Date Title
HUP9800882A2 (hu) Enterális fluoxetin pelletek és eljárás előállításukra
MY116361A (en) Duloxetine enteric pellets
HUP0103844A2 (hu) Késleltetett felszabadulású ranolazin-készítmények
JPS5230402A (en) Multichannel stereo system
HRP20000053B1 (en) Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production
IL142474A0 (en) Pharmaceutical formulation comprising omeprazole
FI970634L (fi) Syklosporiinien uudet, suun kautta annettavat, koostumukseltaan yksinkertaiset valmistemuodot, joista biosaatavuus on hyvä, sekä menetelmä niiden valmistamiseksi
ES2165833T1 (es) Composicion farmaceutica revestida enterica y procedimiento de fabricacion.
HUP9600924A2 (en) Aromatic hydroxamic acid derivatives, their production, use and pharmaceutical compn. contg. the said compds.
NO996433D0 (no) Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav
CA2191178A1 (en) Long-lasting release nifedipine preparation
AR029546A1 (es) Particulas farmaceuticas con sabor enmascarado
WO2001010816A3 (de) Substituierte 2-Dialkylaminoalkylbiphenyl-derivate
AUPR098400A0 (en) Production of radionuclide coated microspheres and seeds
FI853861A0 (fi) Acetaminofen-gelatinkapsel, medelst vilken snabbt erhaolles terapeutisk aktivitet vid oral dosering.
MY118569A (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
IT8420664A0 (it) Procedimento per preparare, una polvere finemente divisa scelta dal gruppo costituito da polvere di diboruro di titanio e polvere di diboruro di zirconio.
NO985145L (no) Farmas°ytiske preparater for forsinket frigj°ring av uoppl°selige, aktive bestanddeler
NO984540D0 (no) Cytokrom P450 transduserende retrovirusvektorer
BG102692A (en) Pharmaceutical forms with delayed release, containing misolastin
AU7752100A (en) C3 binding polypeptide of streptococcus agalactiae, group b streptococcus
AU1044401A (en) A fertiliser including gelatine, and methods of production
TH54044A (th) ฟลูออเซทีนเม็ดกลมชนิดเอนเทอริก
AU5026300A (en) Plasmids and methods for construction of non-redundant, saturation, gene-disruption plant libraries
ECSP982517A (es) Granulos entericos de fluoxetina

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal